ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate

Abstract

We assessed the pharmacokinetics and interaction of ABT-773 in 12 volunteers receiving ABT-773 alone or concomitantly with ranitidine or sucralfate. Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng. h/ml. Coadministration of ranitidine, reduced the C(max) (-25.7%) and AUC(0- infinity ) (-15.8%) significantly. Sucralfate had no impact on the bioavailability of ABT-773.

FIG. 1.

Arithmetic means of measured concentrations of ABT-773 (A) and its metabolite M-1 (B) in plasma after the administration of 150 mg of ABT-773 alone (treatment A) and with ranitidine (treatment B) or sucralfate (treatment C) in 12 healthy volunteers. The direction of the error bars (standard deviation) is upwards for treatment A and downwards for treatments B and C.